Ocugen, Inc.
OCGN
Key stats
- Open
- 0.92
- Day high
- 0.94
- Day low
- 0.86
- Previous close
- 0.96
- Volume
- 6.20M
- VWAP
- 0.90
- 52-week high
- 2.73
- 52-week low
- 0.69
- Market cap
- 325.87M
- Shares out
- 339.31M
- Employees
- 116
- Listed
- 2014
About Ocugen, Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MALVERN, PA · ocugen.com
Options · expiring Nov 20
Nov 12, 3:58 PM ET- Call open interest
- 7.8K
- Put open interest
- 108
- Put/call
- 0.01
- At-the-money IV
- 225.5%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 1 call | 0.03 | Nov 12, 3:06 PM | 20 | 7.4K | 225.5% |
| 0.50 call | 0.40 | Nov 12, 11:39 AM | 6 | 24 | — |
| 1 put | 0.15 | Nov 12, 2:32 PM | 6 | 100 | 199.7% |
| 1.50 call | 0.05 | Nov 10, 9:47 AM | 2 | 391 | — |
| 2 put | 1.18 | Nov 4, 10:51 AM | 2 | 1 | 609.8% |
| 2 call | 0.03 | Nov 9, 9:30 AM | 1 | 4 | — |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $1.95M | $1.49M | $1.53M | — |
| Gross profit | $1.95M | $1.49M | $1.53M | — |
| Operating income | −$17.75M | −$16.44M | −$17.84M | — |
| Net income | −$3.60M | −$24.88M | −$19.18M | — |
| Diluted EPS | -0.01 | -0.07 | -0.06 | — |
| Operating cash flow | −$15.74M | −$12.20M | −$21.79M | −$13.96M |
| Assets | $108.06M | $124.21M | $56.91M | $43.52M |
| Liabilities | $125.74M | $140.76M | $51.10M | $55.68M |
| Equity | −$17.68M | −$16.56M | $5.80M | −$12.17M |
Technicals
Massive · Nov 12, 2026- 50-day average0.95
- 200-day average1.39
- RSI (14 days)49.5
Short interest
Massive · Oct 30, 2026- Oct 30, 2026107.67M shares · 16.4 days to cover
- Oct 15, 2026107.16M shares · 15.8 days to cover
- Sep 30, 2026102.05M shares · 13.7 days to cover
- Sep 15, 2026106.06M shares · 10.4 days to cover
Related companies
MassiveNews coverage
No stories about Ocugen, Inc. right now.